Cargando…
Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization
BACKGROUND: There has been increasing use of extracorporeal membrane oxygenation (ECMO) as bridge to heart transplant (orthotopic heart transplant [OHT]) or left ventricular assist device (LVAD) over the last decade. We aimed to provide insights on the population, outcomes, and predictors for the se...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763251/ https://www.ncbi.nlm.nih.gov/pubmed/34879706 http://dx.doi.org/10.1161/CIRCHEARTFAILURE.121.008777 |
_version_ | 1784633898190241792 |
---|---|
author | Mastoris, Ioannis Tonna, Joseph E. Hu, Jinxiang Sauer, Andrew J. Haglund, Nicholas A. Rycus, Peter Wang, Yu Wallisch, William J. Abicht, Travis O. Danter, Matthew R. Tedford, Ryan J. Fang, James C. Shah, Zubair |
author_facet | Mastoris, Ioannis Tonna, Joseph E. Hu, Jinxiang Sauer, Andrew J. Haglund, Nicholas A. Rycus, Peter Wang, Yu Wallisch, William J. Abicht, Travis O. Danter, Matthew R. Tedford, Ryan J. Fang, James C. Shah, Zubair |
author_sort | Mastoris, Ioannis |
collection | PubMed |
description | BACKGROUND: There has been increasing use of extracorporeal membrane oxygenation (ECMO) as bridge to heart transplant (orthotopic heart transplant [OHT]) or left ventricular assist device (LVAD) over the last decade. We aimed to provide insights on the population, outcomes, and predictors for the selection of each therapy. METHODS: Using the Extracorporeal Life Support Organization Registry between 2010 and 2019, we compared in-hospital mortality and length of stay, predictors of OHT versus LVAD, and predictors of in-hospital mortality for patients with cardiogenic shock that were bridged with ECMO to OHT or LVAD. One hundred sixty-seven patients underwent LVAD versus 234 patients who underwent OHT. RESULTS: The overall use of ECMO has increased from 1.7% in 2010 to 22.2% in 2019. Mortality was similar between groups (LVAD: 28.7% versus OHT: 29.1%) while length of stay was longer for OHT (LVAD: 49.6 versus OHT: 59.5 days, P=0.05). Factors associated with OHT included prior transplant (odds ratio [OR]=31.26 [CI, 3.84–780.5]), use of a temporary pacemaker (OR=6.5 [CI, 1.39–50.15]), and increased use of inotropes on ECMO (OR=3.77 [CI, 1.39–11.07]), whereas LVAD use was associated with weight (OR=0.98 [CI, 0.97–0.99]), cardiogenic shock presentation (OR=0.40 [CI, 0.21–0.78]), previous LVAD (OR=0.01 [CI, 0.0001–0.22]), respiratory failure (OR=0.28 [CI, 0.11–0.70]), and milrinone infusion (OR=0.32 [CI, 0.15–0.67]). Older age (OR=1.07 [CI, 1.02–1.12]), cannulation bleeding (OR=26.1 [CI, 4.32–221.3]), and surgical bleeding (OR=6.7 [CI, 1.26–39.9]) in patients receiving LVAD and respiratory failure (OR=5 [CI, 1.17–23.1]) and continuous renal replacement therapy (OR=3.82 [CI, 1.28–11.9]) in patients receiving OHT were associated with increased mortality. CONCLUSIONS: ECMO use as a bridge to advanced therapies has increased over time, with more patients undergoing LVAD than OHT. Mortality was equal between the 2 groups while length of stay was longer for OHT. |
format | Online Article Text |
id | pubmed-8763251 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-87632512022-01-21 Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization Mastoris, Ioannis Tonna, Joseph E. Hu, Jinxiang Sauer, Andrew J. Haglund, Nicholas A. Rycus, Peter Wang, Yu Wallisch, William J. Abicht, Travis O. Danter, Matthew R. Tedford, Ryan J. Fang, James C. Shah, Zubair Circ Heart Fail Original Articles BACKGROUND: There has been increasing use of extracorporeal membrane oxygenation (ECMO) as bridge to heart transplant (orthotopic heart transplant [OHT]) or left ventricular assist device (LVAD) over the last decade. We aimed to provide insights on the population, outcomes, and predictors for the selection of each therapy. METHODS: Using the Extracorporeal Life Support Organization Registry between 2010 and 2019, we compared in-hospital mortality and length of stay, predictors of OHT versus LVAD, and predictors of in-hospital mortality for patients with cardiogenic shock that were bridged with ECMO to OHT or LVAD. One hundred sixty-seven patients underwent LVAD versus 234 patients who underwent OHT. RESULTS: The overall use of ECMO has increased from 1.7% in 2010 to 22.2% in 2019. Mortality was similar between groups (LVAD: 28.7% versus OHT: 29.1%) while length of stay was longer for OHT (LVAD: 49.6 versus OHT: 59.5 days, P=0.05). Factors associated with OHT included prior transplant (odds ratio [OR]=31.26 [CI, 3.84–780.5]), use of a temporary pacemaker (OR=6.5 [CI, 1.39–50.15]), and increased use of inotropes on ECMO (OR=3.77 [CI, 1.39–11.07]), whereas LVAD use was associated with weight (OR=0.98 [CI, 0.97–0.99]), cardiogenic shock presentation (OR=0.40 [CI, 0.21–0.78]), previous LVAD (OR=0.01 [CI, 0.0001–0.22]), respiratory failure (OR=0.28 [CI, 0.11–0.70]), and milrinone infusion (OR=0.32 [CI, 0.15–0.67]). Older age (OR=1.07 [CI, 1.02–1.12]), cannulation bleeding (OR=26.1 [CI, 4.32–221.3]), and surgical bleeding (OR=6.7 [CI, 1.26–39.9]) in patients receiving LVAD and respiratory failure (OR=5 [CI, 1.17–23.1]) and continuous renal replacement therapy (OR=3.82 [CI, 1.28–11.9]) in patients receiving OHT were associated with increased mortality. CONCLUSIONS: ECMO use as a bridge to advanced therapies has increased over time, with more patients undergoing LVAD than OHT. Mortality was equal between the 2 groups while length of stay was longer for OHT. Lippincott Williams & Wilkins 2021-12-09 /pmc/articles/PMC8763251/ /pubmed/34879706 http://dx.doi.org/10.1161/CIRCHEARTFAILURE.121.008777 Text en © 2021 The Authors. https://creativecommons.org/licenses/by-nc-nd/4.0/Circulation: Heart Failure is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made. |
spellingShingle | Original Articles Mastoris, Ioannis Tonna, Joseph E. Hu, Jinxiang Sauer, Andrew J. Haglund, Nicholas A. Rycus, Peter Wang, Yu Wallisch, William J. Abicht, Travis O. Danter, Matthew R. Tedford, Ryan J. Fang, James C. Shah, Zubair Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization |
title | Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization |
title_full | Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization |
title_fullStr | Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization |
title_full_unstemmed | Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization |
title_short | Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization |
title_sort | use of extracorporeal membrane oxygenation as bridge to replacement therapies in cardiogenic shock: insights from the extracorporeal life support organization |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763251/ https://www.ncbi.nlm.nih.gov/pubmed/34879706 http://dx.doi.org/10.1161/CIRCHEARTFAILURE.121.008777 |
work_keys_str_mv | AT mastorisioannis useofextracorporealmembraneoxygenationasbridgetoreplacementtherapiesincardiogenicshockinsightsfromtheextracorporeallifesupportorganization AT tonnajosephe useofextracorporealmembraneoxygenationasbridgetoreplacementtherapiesincardiogenicshockinsightsfromtheextracorporeallifesupportorganization AT hujinxiang useofextracorporealmembraneoxygenationasbridgetoreplacementtherapiesincardiogenicshockinsightsfromtheextracorporeallifesupportorganization AT sauerandrewj useofextracorporealmembraneoxygenationasbridgetoreplacementtherapiesincardiogenicshockinsightsfromtheextracorporeallifesupportorganization AT haglundnicholasa useofextracorporealmembraneoxygenationasbridgetoreplacementtherapiesincardiogenicshockinsightsfromtheextracorporeallifesupportorganization AT rycuspeter useofextracorporealmembraneoxygenationasbridgetoreplacementtherapiesincardiogenicshockinsightsfromtheextracorporeallifesupportorganization AT wangyu useofextracorporealmembraneoxygenationasbridgetoreplacementtherapiesincardiogenicshockinsightsfromtheextracorporeallifesupportorganization AT wallischwilliamj useofextracorporealmembraneoxygenationasbridgetoreplacementtherapiesincardiogenicshockinsightsfromtheextracorporeallifesupportorganization AT abichttraviso useofextracorporealmembraneoxygenationasbridgetoreplacementtherapiesincardiogenicshockinsightsfromtheextracorporeallifesupportorganization AT dantermatthewr useofextracorporealmembraneoxygenationasbridgetoreplacementtherapiesincardiogenicshockinsightsfromtheextracorporeallifesupportorganization AT tedfordryanj useofextracorporealmembraneoxygenationasbridgetoreplacementtherapiesincardiogenicshockinsightsfromtheextracorporeallifesupportorganization AT fangjamesc useofextracorporealmembraneoxygenationasbridgetoreplacementtherapiesincardiogenicshockinsightsfromtheextracorporeallifesupportorganization AT shahzubair useofextracorporealmembraneoxygenationasbridgetoreplacementtherapiesincardiogenicshockinsightsfromtheextracorporeallifesupportorganization |